Long Non-coding RNA Structure and Function: Is There a Link?

Anna Zampetaki**, Andreas Albrecht² and Kathleen Steinhofel³

1 King's British Heart Foundation Centre, King's College London, London, United Kingdom, 2 Faculty of Science and Technology, Middlesex University, London, United Kingdom, 3 Department of Informatics, King's College London, London, United Kingdom

RNA has emerged as the prime target for diagnostics, therapeutics and the development of personalized medicine. In particular, the non-coding RNAs (ncRNAs) that do not encode proteins, display remarkable biochemical versatility. They can fold into complex structures and interact with proteins, DNA and other RNAs, modulating the activity, DNA targets or partners of multiprotein complexes. Thus, ncRNAs confer regulatory plasticity and represent a new layer of epigenetic control that is dysregulated in disease. Intriguingly, for long non-coding RNAs (lncRNAs, >200 nucleotides length) structural conservation rather than nucleotide sequence conservation seems to be crucial for maintaining their function. LncRNAs tend to acquire complex secondary and tertiary structures and their functions only impose very subtle sequence constraints. In the present review we will discuss the biochemical assays that can be employed to determine the lncRNA structural configurations. The implications and challenges of linking function and lncRNA structure to design novel RNA therapeutic approaches will also be analyzed.

**Correspondence:** Anna Zampetaki
anna.zampetaki@kcl.ac.uk

Keywords: non-coding RNA, lncRNA, RNA structure, gene editing, cardiovascular diseases

INTRODUCTION

The HUMAN GENOME project has transformed our understanding of the basic unit of genetic information with RNA emerging as a versatile regulator of central cellular processes (Thum and Condorelli, 2015). The non-coding RNAs (ncRNAs), transcripts that do not encode proteins comprise the biggest class and are arbitrarily divided into small (<200 nucleotides) and long non-coding RNAs (lncRNA (>200 nucleotides). MicroRNAs (miRNAs) are the best studied small ncRNAs, representing an additional layer of posttranscriptional regulators that absorb perturbations and ensure the robustness of biological systems (Liu and Olson, 2010; Ebert and Sharp, 2012; Rotllan et al., 2016).

Substantial effort has now been directed toward dissecting the function of IncRNAs. In the cardiovascular system, IncRNAs were reported to play key roles in physiology and disease and targeting IncRNAs for novel therapeutic interventions has been explored (Uchida and Dimmeler, 2015; Boon et al., 2016; Buhrke et al., 2018). Here we will discuss the experimental tools to determine the RNA structure that can offer unique insights into the IncRNA function in the cardiovascular system.
CHALLENGES IN ASSESSING IncRNA FUNCTIONALITY

The unique features of IncRNAs have been extensively investigated (Guttman and Rinn, 2012; Ulitsky and Bartel, 2013; Bar et al., 2016; Ulitsky, 2016). Several characteristics of IncRNAs make functional evaluation challenging. Typically, IncRNAs display poor conservation across species showing only “patches” of conserved bases surrounded by large seemingly unconstrained sequences (Ponjavic et al., 2007; Guttman et al., 2009; Necsulea et al., 2014; Washietl et al., 2014). Additionally, IncRNAs exhibit low abundance that restricts their mode and sites of action (Mercer et al., 2008; Cabili et al., 2011, 2015; Washietl et al., 2014; Ulitsky, 2016; Wilk et al., 2016; Jandura and Krause, 2017). In terms of the modes of function, both cis- and trans-regulatory activity have been described (Mercer and Mattick, 2013). As cis-regulators, IncRNAs exert their function on neighboring genes on the same allele from which they are transcribed, displaying expression correlation and perturbation in an allele-specific manner. CARMEN, an enhancer associated IncRNA and a crucial regulator of cardiac specification in human cardiac progenitor cells was shown in cis to control the expression of miR-143/145 (Ounzain et al., 2015). On the other hand, acting in trans-IncRNAs can control gene expression at a distance from their transcription site, by altering the chromatin state, influencing the nuclear structure or regulating protein function (Vance and Ponting, 2014; Kopp and Mendell, 2018).

Intriguingly, for some low abundance IncRNAs the act of transcription seems to be more important than the transcript itself. In a seminal study, Engreitz et al. (2016) genetically manipulated 12 genomic loci that produce IncRNAs to find that 5 loci influenced the expression of a neighboring gene in cis. The expression of the IncRNAs transcripts themselves was not required but instead processes associated with their transcription were critical (Engreitz et al., 2016).

THE RNA INTERACTOME

The above functional versatilities of IncRNAs stem from their ability to conform to different structures and molecular interactions with proteins, RNA and DNA (Guttman and Rinn, 2012; Marchese et al., 2017). In ribonucleoprotein complexes (RNPs), IncRNAs may act as scaffolds to stabilize the complexes, directing them to specific subcellular loci or the DNA. In endothelial cells, interaction of the IncRNA MANTIS with the ATPase catalytic subunits confers specificity to the switch/suicre non-ferentable (SWI/SNF) chromatin remodeling complex directing it to a subset of angiogenic genes and facilitating nucleosome remodeling and transcription initiation (Leisegang et al., 2017; Zampetaki and Mayr, 2017). In fact binding of IncRNA to specific ATPase subunits of the SWI/SNF complex is a common regulatory mechanism (Cajigas et al., 2015; Zhu et al., 2016).

Interaction of IncRNAs with chromatin complexes is particularly important as these IncRNA-RNPs can trigger chromatin modifications through interference with the chromatin-modifying machinery (Tsai et al., 2010; Brockdorff, 2013; Simon et al., 2013). In the heart, Chaer a cardiac enriched IncRNA acts as an epigenetic switch by interfering with the polycomb repressive complex 2 (PRC2) and inhibiting H3K27m3 at genes involved in cardiac hypertrophy (Wang et al., 2016), while mesoderm faith determining IncRNA Fendrr can bind to both PRC2 and Trithorax group/MLL (TrxG/MLL) complexes acting as a fine tuner (Grote et al., 2013).

Apart from proteins, interaction of IncRNAs with DNA has also been described. This can lead to the formation of RNA-DNA triplex, a structure that is widespread in vivo and facilitates target gene recognition by IncRNAs (Mondal et al., 2015). This interaction was elegantly demonstrated in MEG3, a cardiac fibroblast enriched IncRNA that promotes fibrosis (Piccoli et al., 2017). MEG3 interacts with the PRC2 complex and forms RNA-DNA triplex structures through GA-rich sequence binding sites. Chromatin RNA immunoprecipitation revealed that MEG3 modulates the activity of TGF-b pathway genes and target recognition occurs via the triplex structures (Mondal et al., 2015).

Long non-coding RNA regulatory functions also rely on RNA–RNA interactions. Crosstalk with miRNAs creates an intricate network that exerts post-transcriptional regulation of gene expression. IncRNAs can harbor miRNA binding sites and act as molecular decoys or sponges that sequester miRNAs away from other transcripts. Noteworthy, competition between IncRNAs and miRNAs for binding to target mRNAs has been reported and leads to de-repression of gene expression (Yoon et al., 2014; Ballantyne et al., 2016). Finally, IncRNAs may contain embedded miRNA sequences and serve as a source of miRNAs (Piccoli et al., 2017).

LINKING RNA STRUCTURE TO FUNCTION

RNA molecules adopt higher order tertiary interactions (Staple and Butcher, 2005; Wan et al., 2011). Although links between structure and function are emerging, the structural domains that dominate the RNA interactome are still not well defined. The functional implications of transcript structure are better understood in the processing the primary miRNAs (primiRNAs) to mature miRNAs. Using multiple mutagenesis assays, the secondary structures such as stem length, hairpin pairing, bulge size and position, and apical loop size that contribute to effective miRNA biogenesis were defined (Auyeung et al., 2013; Fang and Bartel, 2015; Nguyen et al., 2015; Roden et al., 2017). In clustered miRNAs that consist of multiple miRNA genes, the tertiary structure was also proposed to contribute to the processing to individual mature miRNAs. An autoregulatory role for the tertiary structure of miR-17~92 cluster in its maturation and binding of auxiliary factors to conserved terminal loops was shown (Chakraborty et al., 2012). Recently, in the miR-497~195 cluster, mutations in miR-195a hairpin were reported to affect the processing of miR-497a that resides in the same
cluster. Computational analysis highlighted differences in the
tertiary structure of the primiRNA in mutants that may affect the
maturation process (Lataniotis et al., 2017). On a different note, in
primiR-30c-1 the tertiary structure promotes the interaction with
SRSF3, an SR protein family member that facilitates primiRNA
recognition and processing. A single G/A sequence variation
leads to a structural rearrangement of the apical region of the
primiRNA affecting the conserved residues placed at the basal
part of the stem and mature miRNA generation (Fernandez et al.,
2017).

In IncRNAs, selection acting on structure rather than primary
sequence may explain the rapid rate of evolution, that led to
the “RNA modular code” hypothesis based on the view that
selection acts on structural domains (Wutz et al., 2002; Tsai
et al., 2010; Gutmann and Rinn, 2012). Some experimental
evidence supports this concept. The MEG3 IncRNA gene contains
three distinct structure modules M1, M2, and M3. Deletion
analysis showed that motifs M2 and M3 are important for p53
activation. Intriguingly, a hybrid MEG3 transcript in which half
of the primary sequence in the M2 motif was replaced by an
entirely unrelated artificial sequence that displayed a similar
structure was fully functional in stimulating p53-mediated
transcription (Zhang et al., 2010).

RNA STRUCTURE DETERMINATION
METHODS

Chemical and enzymatic probing methods can provide an
understanding of the secondary structure of RNA (Ehresmann
et al., 1987). Enzymatic probing relies on nucleases that bind
to paired and unpaired RNA and digest it to generate RNA
fragments that can be analyzed. On the other hand, in chemical
probing small size chemicals that react and covalently modify
solvent accessible nucleotides are used. Following modification
or cleavage, positions are typically mapped by reverse transcription,
which either stops or introduces a mutation into the cDNA
(Wilkinson et al., 2006). An analysis of the resulting cDNA is
then used to determine the nucleotide position and modification
frequency. Next generation sequencing (NGS) can be applied
directly to sequence the cDNA products. This allows RNA
structural characterization at a transcriptome-wide level in a
single experiment (Lucks et al., 2011; Incarnato et al., 2014;
Loughrey et al., 2014; Rouskin et al., 2014). Although initially the
technologies were established to analyze RNA structure in vitro,
structural characterization in vivo mainly through the use of
probes that can diffuse quickly across membranes has also been
reported (Spitale et al., 2013; Ding et al., 2014; Spitale et al., 2015;
Flynn et al., 2016).

ENZYMATIC PROBING

PARS

PARS (parallel analysis of RNA structure) is a high-throughput
enzymatic probing method that measures the structural
properties of isolated polyadenylated transcript pools that are
renatured in vitro and treated with RNase V1 or S1. RNase V1 and
RNase S1 cleave the 3’ phosphodiester bonds of double-stranded
and single-stranded RNA, respectively, allowing evaluation of the
double- or single-stranded conformation (Kertesz et al., 2010).

Frag-Seq

Frag-Seq (fragmentation sequencing) is an enzymatic method
that uses a nuclease P1 to specifically cleave single-stranded
RNA. High-throughput sequencing then analyses the fragments
generated. This workflow provides an “RNA accessibility
profile” that is likened to the DNase hypersensitivity assays
on chromatin (Underwood et al., 2010). Noteworthy, Frag-
seq isolates fragments <200 bases after RNase P1 cleavage,
hence large RNAs maybe underrepresented. As Frag-seq and
PARS can provide complementary data a combined approach
could improve the accuracy of genome-wide RNA structure
measurements (Wan et al., 2011).

CHEMICAL PROBING

DMS Probing

The dimethyl sulfate (DMS) is a base specific reagent that can
bind and alter the methylation state of unpaired adenosine and
cytosine nucleotides (Tijerina et al., 2007; Rouskin et al., 2014).
DMS footprinting is optimized for structural analysis of RNA.
Protein binding to RNA generates a “footprint” that can be traced
due to alterations in the RNA structure. The transcript size that
can be evaluated is rather small (<500 nt) but this method can be
performed both in vitro and in vivo as DMS can easily penetrate
the cell membrane. DMS-seq that combines DMS methylation
with NGS was recently performed in vivo (Ding et al., 2014;
Rouskin et al., 2014).

Targeted Structure-Seq

Targeted Structure-Seq relies on RNA methylation by DMS being
performed in vivo. Subsequently, RNA is isolated from cells and
the methylation sites are determined by employing gene specific
primers for the reverse transcription reaction. Sequencing of the
DMS derived fragments can be used to assess the cellular
conformation of the RNA. Based on this method, structural
models of elements within Xist were developed (Fang et al., 2015).
Although initially reported using DMS this workflow can be
adapted for other probing reagents.

SHAPE

SHAPE (selective 2’-hydroxyl acylation by primer extension) can
interrogate the RNA structure both in vitro and in vivo using
the chemical NMIA and its derivatives to detect flexible regions
in RNA secondary structure (Wilkinson et al., 2006; Weeks and
Mauger, 2011). Several SHAPE reagents have been tested in order
to improve the signal to background ratio (Lee et al., 2017).
In SHAPE, the 2’-hydroxyl groups of all four nucleotides are
selectively acylated when flexible and unpaired. This results in
the formation of covalent SHAPE adducts that block the reverse
transcription leading to truncated cDNA fragments. SHAPE
reactivities can then be used to model secondary structures and quantify any process that modulates RNA dynamics.

**SHAPE-MaP**
SHAPE-MaP (SHAPE and mutational profiling) was the first to combine the SHAPE protocol with NGS. Initially performed and reported to define the HIV-1 RNA genome, SHAPE-MaP is a highly sensitive technique that allowed rapid, de novo discovery and direct validation of new functional motifs (Siegfried et al., 2014; Mustoe et al., 2018).

**In-cell SHAPE-Seq**
In-cell SHAPE-Seq is a modification of the SHAPE-Seq technique that combines the SHAPE-seq with gene expression measurements to elucidate the association of RNA structure and function in vivo. It revealed translational regulatory mechanisms in *E. coli* in vivo (Watters et al., 2016).

**icSHAPE-seq**
icSHAPE-seq (in vivo click SHAPE sequencing) uses the in-cell SHAPE chemical NAI-N3 followed by selective chemical enrichment of NAI-N3-modified RNA that provides an improved signal-to-noise ratio (Flynn et al., 2016). Follow-up NGS allows accurate identification at single-nucleotide resolution. In mouse embryonic stem cells it was shown that in vitro RNA folding is programmed entirely by the sequence, whereas in vivo, the RNA structure depends on the context of intracellular environment and interaction with RNA binding proteins that may lead to focal structural rearrangements (Spitale et al., 2015). Hence, this assay offers the exciting possibility of viewing the RNA structure in vivo in the presence or absence of stimulation.

**RNA STRUCUTUROME AND INTERACTOME DETERMINATION**

**PARIS**
PARIS (psoralen analysis of RNA interactions and structures) was recently developed to determine both RNA structure and interactions in vivo. It uses the highly specific and reversible nucleic acid crosslinker psoralen-derivative 4′-aminomethyltrioxsalen to fix base pairs in living cells. Subsequently, partial RNase and complete proteinase digestion lead to purification of a set of small crosslinked and directly base-paired RNA fragments. Purification of the crosslinked fragments using 2D electrophoresis, followed by proximity ligation of duplex RNA fragments, reversal of crosslinks, and high throughput sequencing reveals the direct base pairing between fragments. Based on these reads, models of RNA structures and interactions can be generated with high specificity and sensitivity (Lu et al., 2016). Using this approach a model for the higher order structure of Xist was interrogated (Lu et al., 2016). Encouragingly, these findings are in agreement with crystallographic studies of the defined domains in vitro (Arieti et al., 2014).

**IncRNA STRUCTURE DETERMINATION**
Structure determination of IncRNA in vivo is extremely challenging as they are highly heterogenic with regions with well-defined base-pairing, others without base-pairing and regions with multiple structures. Additionally, IncRNAs may stretch across thousands of nucleotides, they are expressed in low abundance and tend to be part of multicomponent complexes (Busan and Weeks, 2017). Nevertheless, the structure of several IncRNAs has been experimentally determined (Table 1).

**Xist**
This is a very long IncRNA (17,000 nucleotides) controlling X chromosome inactivation. It spreads across the entire chromosome while triggering stable epigenetic modifications through recruitment of the PRC2 complex and enrichment for the H3K27me3 repressive chromatin modification (Simon et al., 2013; Fang et al., 2015; Smola et al., 2016). *In vivo* SHAPE data identified 33 regions in Xist that form well-defined secondary structures linked by structurally variable and dynamic regions.

**RepA**
This is a 1,600 nucleotides mouse IncRNA encoded by an internal promoter on the Xist-gene sense strand. Applying SHAPE and DMS chemical probing in vitro, an intricate structure of three independently folding modules was revealed. Phylogenetic analysis and computational 3D modeling demonstrated a defined tertiary architecture that can form autonomously in the absence of protein partners (Liu et al., 2017a).

**Rox1/Rox2**
In Drosophila dosage compensation is achieved using two IncRNAs that are transcribed from the X chromosome. RNA on the X 1 and 2 (roX1 and roX2) are 3,700 and 1,200 nucleotides in length, respectively. *In vitro* SHAPE probing and PARS analysis revealed common, conserved and distinct structural motifs that may function as targeting sites and assembly platforms for the male specific lethal complex (Ilik et al., 2013).

**SRA**
The human steroid receptor RNA activator (SRA) is an 870 nucleotide IncRNA that is derived from a gene encoding both IncRNA and protein coding transcripts. The structure of SRA was experimentally interrogated using SHAPE and DMS chemical probing in vitro. In parallel, RNase V1 enzymatic probing was performed. It was shown that SRA consists of four distinct domains with a variety of secondary structures (Novikova et al., 2012). More importantly, comparative structural analysis between mouse and human strongly suggested that a large number of evolutionary changes had minimal mutational effect on the protein derived from the locus while stabilizing the RNA structural core (Novikova et al., 2012).

**HOTAIR**
Associated with Sporadic Thoracic Aortic Aneurysm through regulation of extracellular matrix deposition and human...
aortic smooth muscle cells apoptosis, this lncRNA plays a key role in the cardiovascular system (Guo et al., 2017). In non-end stage heart failure patients HOTAIR was among a panel of lncRNAs that were significantly modulated (Greco et al., 2016). A protective role of HOTAIR in cardiomyocytes (Gao et al., 2017) and as a circulating biomarker for acute myocardial infarction and congenital heart diseases were also proposed (Jiang et al., 2018). Hotair is 2,148 nucleotides long making the structural determination extremely challenging. To address this issue a non-denaturing purification protocol was introduced at a DSB site (Lin et al., 2014) in primary cells and enzymatic probing. Good agreement with RNase VI enzymatic probing.

**FUTURE DIRECTIONS**

RNA structure determination combined with genetic manipulations can elucidate the important functional domains of lncRNAs. To this end, advanced experimental tools, bioinformatics and genome engineering should be integrated. The CRISPR/Cas9 gene editing system emerged as a robust technology that can be used to generate targeted modifications at precise genomic loci. Cas9, a nuclease that can induce double-stranded breaks (DSBs) to the DNA, can be guided in the immediate vicinity of the proto-adjacent motif NGG by an RNA molecule (sgRNA) consisting of a small 20 nucleotide long variable sequence and an adaptor transactivating RNA. Precise insertions, deletions, or base substitutions can be introduced at a DSB site (Lin et al., 2014) in primary cells and in vivo in mouse models of disease (Platt et al., 2014; Abrahimi et al., 2015). A modified version of the CRISPR/Cas9 system has recently been employed for genome scale screenings of functional lncRNAs. This CRISPR interference approach uses a nuclease dead Cas9 (dCas9) that is not capable of inducing DSB to the DNA. Fused to a repressor domain (e.g., KRAB) (Liu et al., 2017b) or an activation domain (e.g., VP64) (Konermann et al., 2015; Bester et al., 2018) dCas9 and can be guided by sgRNAs to specific loci in the upstream regulatory region to trigger repression or activation of lncRNA transcription, respectively.

**TABLE 1 | Structural Determination of IncRNAs.**

| lncRNA (size)       | Mode of action | Function                                                                 | Structure                                                                 | Probing techniques                                                                 | Reference                                      |
|---------------------|----------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------------------------|------------------------------------------------|
| Xist (17,000 nucleotides) | cis            | X-chromosome inactivation.                                              | Regions A-F with distinct repeat sequences.                               | In vivo and in vitro SHAPE-MaP Targeted structure Seq.PARSIS                       | Underwood et al., 2010; Weeks and Mauger, 2011; Incarnato et al., 2014; Engert et al., 2016 |
| RepA (1,600 nucleotides) | cis            | Encoded by an internal promoter on the Xist gene sense strand.          | Three folding modules.                                                    | In vitro using chemical probing with SHAPE and DMS reagents.                      | Lee et al., 2017                                |
| Rox1 (3,700 nucleotides) Rox2 (1,200 nucleotides) | cis and trans | Male specific nuclear RNAs. Dosage compensation.                       | Rox1: three stable helices connected by flexible linker regions. Rox2: two clusters of tandem stem-loops. | In vitro using chemical probing with SHAPE and PARS analysis. Both methods independently support the rox2 structure model. | Siegfried et al., 2014                          |
| SPA (870 nucleotides) | trans          | Interacts with SRA protein to regulate cardiac muscle differentiation.   | Four distinct domains.                                                     | In vitro SHAPE and DMS chemical probing. Good agreement with RNase VI enzymatic probing. | Watters et al., 2016; Mustoe et al., 2018      |
| HOTAIR (2,148 nucleotides) | trans          | Associated with sporadic thoracic aortic aneurysm and non-end stage heart failure. Circulating biomarker for acute myocardial infarction and congenital heart diseases. | Four structural modules.                                                  | In vitro using chemical probing with SHAPE and DMS reagents.                      | Arieti et al., 2014; Lu et al., 2016; Smola et al., 2016; Watters et al., 2016; Busan and Weeks, 2017 |
| Braveheart (590 nucleotides) | trans          | Cardiovascular lineage commitment.                                       | Three domains. Critical structure: a 5′ asymmetric G-rich internal loop (AGIL). | In vitro using chemical probing with SHAPE and DMS reagents.                      | Liu et al., 2017a                               |

**Braveheart**

*Braveheart* is a 590 nucleotide lncRNA that acts in trans to regulate cardiovascular lineage commitment. Its secondary structure was experimentally assessed using SHAPE and DMS probing in vitro. It emerged that *Braveheart* is organized into a highly intricate modular structure comprising of three domains, consisting of 12 helices, 8 terminal loops, 5 sizeable internal loops, and a five-way junction. Intriguingly, it includes a 5′ asymmetric G-rich internal loop (AGIL) and a 55 nucleotide stretch at the 3′ end exhibiting high reactivity suggesting low probability of structure. Genetic deletion of this specific 11 nucleotide fragment demonstrated that the AGIL motif is essential for mouse embryonic stem cell differentiation to cardiomyocytes through binding of the zing-finger protein CNBP/ZNF9 (Xue et al., 2016).
Such approaches are extremely useful to test the functionality of IncRNAs in a high throughput manner.

Once specific IncRNAs are identified, technologies that can define the IncRNA structure in vivo are critical to determine IncRNA modules and structural domains. RNA structure determination can be coupled with comparative genomics analysis that will take into consideration the positional conservation and the fact that IncRNAs may rely on short elements rather than long stretches of conserved sequences. Genetic studies that can target precisely these structural domains while maintaining the expression of the IncRNA (Matsumoto et al., 2017) will delineate the functional impact of these motifs. The use of CRISPR/Cas9 gene editing in induced pluripotent stem cells that can be clonally expanded, engineered to harbor defined deletions of the structural motifs and differentiated to other cell types (Cochrane et al., 2017; Granata et al., 2017) can provide conclusive evidence for the functional impact of these domains in the cardiovascular system. The potential of these elements as novel targets could be explored further for precise interventions suitable for therapeutic applications.

AUTHOR CONTRIBUTIONS
AZ initiated the study, designed its structure, and wrote the manuscript. AA provided conceptual advice and revised the manuscript. KS designed the review structure, provided conceptual advice, and revised the manuscript. All authors read and approved the submitted version.

FUNDING
This work was funded by the British Heart Foundation. AZ is an Intermediate Fellow of the British Heart Foundation (FS/13/18/30207).

REFERENCES
Abrahimi, P., Chang, W. G., Kluger, M. S., Qyang, Y., Tellides, G., Saltzman, W. M., et al. (2015). Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9. Circ. Res. 117, 121–128. doi: 10.1161/CIRCRESAHA.117.306290

Arieti, F., Gabus, C., Tambalo, M., Huet, T., Round, A., and Thore, S. (2014). The crystal structure of the Split End protein SHARP adds a new layer of complexity to proteins containing RNA recognition motifs. Nucleic Acids Res. 42, 6742–6752. doi: 10.1093/nar/gku277

Auyeung, V. C., Ulitsky, I., McGeary, S. E., and Bartel, D. P. (2013). Beyond the menu of features that define primary-sequence determinants license pri-miRNA hairpins for processing. Cell 152, 844–858. doi: 10.1016/j.cell.2013.01.031

Ballantyne, M. D., McDonald, R. A., and Baker, A. H. (2016). IncRNA/MicroRNA interactions in the vasculature. Clin. Pharmacol. Ther. 99, 494–501. doi: 10.1002/cpt.355

Bar, C., Chatterjee, S., and Thum, T. (2016). Long noncoding RNAs in cardiovascular pathology, diagnosis, and therapy. Circulation 134, 1484–1499. doi: 10.1161/CIRCULATIONAHA.116.023686

Bester, A. C., Lee, J. D., Chavez, A., Lee, Y. R., Nachmani, D., Vora, S., et al. (2018). An integrated genome-wide CRISPRa approach to functionalize IncRNAs in drug resistance. Cell 173, 694e20–664e20. doi: 10.1016/j.cell.2018.03.052

Boon, R. A., Jae, N., Holdt, L., and Dimmeler, S. (2016). Long noncoding RNAs: from clinical genetics to therapeutic targets? J. Am. Coll. Cardiol. 67, 1214–1226. doi: 10.1016/j.jacc.2015.12.051

Brockdorff, N. (2013). Noncoding RNA and polycomb recruitment. Mol. Cell 49, 97–109. doi: 10.1016/j.molcel.2013.06.017

Buhrk, A., Bar, C., and Thum, T. (2018). [Non-coding RNA: innovative regulators with therapeutic perspective]. Herz 43, 115–122. doi: 10.1007/s00059-017-4660-4

Busan, S., and Weeks, K. M. (2017). Visualization of RNA structure models within the integrative genomics viewer. RNA 23, 1012–1018. doi: 10.1261/rna.060194.116

Cabili, M. N., Dunagin, M. C., McClanahan, P. D., Biaesch, A., Padovan-Merhar, O., Regev, A., et al. (2015). Localization and abundance analysis of human IncRNAs at single-cell and single-molecule resolution. Genome Biol. 16:20. doi: 10.1186/s13059-015-0586-4

Cabili, M. N., Trapnell, C., Goff, L., Koziol, M., Tazon-Vega, B., Regev, A., et al. (2011). Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 25, 1915–1927. doi: 10.1101/gad.17446611

Cajigas, I., Leib, D. E., Cochrane, J., Luo, H., Swyter, K. R., Chen, S., et al. (2015). Evf2 IncRNA/BRG1/DLX1 interactions reveal RNA-dependent inhibition of chromatin remodeling. Development 142, 2641–2652. doi: 10.1242/dev.126318

Chakraborty, S., Mehtab, S., Patwardhan, A., and Krishnan, Y. (2012). Pri-miR-17-92a transcript folds into a tertiary structure and autoregulates its processing. RNA 18, 1014–1028. doi: 10.1261/rna.031039.111

Cochrane, A., Kelaini, S., Tsifaki, M., Bojdo, J., Vila-Gonzalez, M., Drehmer, D., et al. (2017). Quaking is a key regulator of endothelial cell differentiation, neovascularization, and angiogenesis. Stem Cells 35, 952–966. doi: 10.1002/stem.2594

Ding, Y., Tang, Y., Kwok, C. K., Zhang, Y., Bevilacqua, P. C., and Assmann, S. M. (2014). In vivo genome-wide profiling of RNA secondary structure reveals novel regulatory features. Nature 505, 696–700. doi: 10.1038/nature12756

Ebert, M. S., and Sharp, P. A. (2012). Roles for microRNAs in conferring robustness to biological processes. Cell 149, 515–524. doi: 10.1016/j.cell.2012.04.005

Ebert, M. S., and Sharp, P. A. (2012). Roles for microRNAs in conferring robustness to biological processes. Cell 149, 515–524. doi: 10.1016/j.cell.2012.04.005

Ehresmann, C., Baudin, F., Mougel, M., Romby, P., Ebel, J. P., and Ehresmann, B. (1987). Probing the structure of RNAs in solution. Nucleic Acids Res. 15, 9109–9128.

Engert, J. M., Haines, J. E., Perez, E. M., Munson, G., Chen, J., Kane, M., et al. (2016). Local regulation of gene expression by IncRNA promoters, transcription and splicing. Nature 539, 452–455. doi: 10.1038/nature20149

Fang, R., Moss, W. N., Rutenberg-Schoenberg, M., and Simon, M. D. (2015). Probing Xist RNA structure in cells using targeted structure-seq. PLoS Genet. 11:e1005368. doi: 10.1371/journal.pgen.1005368

Fang, W., and Bartel, D. P. (2015). The menu of features that define primary micrornas and enable de novo design of MicroRNA genes. Mol. Cell 60, 131–145. doi: 10.1016/j.molcel.2015.08.015

Fernandez, N., Cordiner, R. A., Young, R. S., Hug, N., Macias, S., and Caceres, J. F. (2017). Genetic variation and RNA structure regulate microRNA biogenesis. Nat. Commun. 8:15114. doi: 10.1038/ncomms15114

Flyn, R. A., Zhang, Q. C., Spital, R. C., Lee, B., Mumbach, M. R., and Chang, H. Y. (2016). Transcriptome-wide interrogation of RNA secondary structure in living cells with isSHAPE. Nat. Protoc. 11, 273–290. doi: 10.1038/nprot.2016.011

Gao, L., Liu, Y., Guo, S., Yao, R., Wu, L., Xiao, L., et al. (2017). Circulating long noncoding RNA HOTAIR is an essential mediator of acute myocardial infarction. Cell Physiol. Biochem. 44, 1497–1508. doi: 10.1159/000485588

Granata, A., Serrano, F., Bernard, W. G., McNamara, M., Low, L., Sastry, P., et al. (2017). An iPSC-derived vascular model of Marfan syndrome identifies key mediators of smooth muscle cell death. Nat. Genet. 49, 97–109. doi: 10.1038/ng.3723

Greco, S., Zaccagnini, G., Perfetti, A., Fuschi, P., Valaperta, R., Voellenkle, C., et al. (2016). Long noncoding RNA dysregulation in ischemic heart failure. J. Transl. Med. 14:183. doi: 10.1186/s12967-016-0926-5

Grote, P., Wittler, L., Hendrix, D., Koch, F., Wahrisch, S., Beisaw, A., et al. (2013). The tissue-specific IncRNA Fendr is an essential regulator of heart and body wall development in the mouse. Dev. Cell 24, 206–214. doi: 10.1016/j.devcel.2012.12.012
Marchese, F. P., Raimondi, I., and Huarte, M. (2017). The multidimensional mechanisms of long non coding RNA function. Genome Biol. 18:206. doi: 10.1186/s13059-017-1348-2

Matsumoto, A., Pasut, A., Matsumoto, M., Yamashita, R., Fung, J., Monteleone, E., et al. (2017). mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide. Nature 541, 228–232. doi: 10.1038/nature21034

Mercer, T. R., Dinger, M. E., Sunkin, S. M., Mehler, M. F., and Mattick, J. S. (2008). Specific expression of long non-coding RNAs in the mouse brain. Proc. Natl. Acad. Sci. U.S.A. 105, 716–721. doi: 10.1073/pnas.0706729105

Mercer, T. R., and Mattick, J. S. (2013). Structure and function of long non-coding RNAs in epigenetic regulation. Nat. Struct. Mol. Biol. 20, 300–307. doi: 10.1038/nsmb.2480

Mondal, T., Subhash, S., Vaid, R., Enroth, S., Uday, S., Reimius, B., et al. (2015). MEG3 long noncoding RNA regulates the TGF-beta pathway genes through formation of RNA-DNA triple structures. Nat. Commun. 6:7743. doi: 10.1038/ncomms8743

Mustoe, A. M., Busan, S., Rice, G. M., Hajdin, C. J., Peterson, B. K., Ruda, V. M., et al. (2018). Pervasive regulatory functions of mRNA structure revealed by high-resolution SHAPE probing. Cell 173, 181.e1–185.e18. doi: 10.1016/j.cell.2018.02.034

Necsulea, A., Soumillon, M., Warnefors, M., Liechti, A., Daish, T., Zeller, U., et al. (2014). The evolution of IncRNA repertoires and expression patterns in tetrapods. Nature 505, 635–640. doi: 10.1038/nature12943

Nguyen, T. A., Jo, M. H., Choi, Y. G., Park, J., Kwon, S. C., Hohng, S., et al. (2015). Functional anatomy of the human microprocessor. Cell 161, 1374–1387. doi: 10.1016/j.cell.2015.05.010

Novikova, I. V., Hennelly, S. P., and Sanbonmatsu, K. Y. (2012). Structural architecture of the human long non-coding RNA, steroid receptor RNA activator. Nucleic Acids Res. 40, 5034–5051. doi: 10.1093/nar/gks071

Ounzain, S., Micheletti, R., Arna, C., Plaisance, L., Cecci, D., Schroen, B., et al. (2015). CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis. J. Mol. Cell Cardiol. 89, 98–112. doi: 10.1016/j.yjcc.2015.09.016

Piccoli, M. T., Gupta, S. K., Viereck, J., Foinquinos, A., Samolovac, S., Kramer, F. L., et al. (2017). Inhibition of the cardiac fibroblast-enriched IncRNA Meg3 prevents cardiac fibrosis and diastolic dysfunction. Circ. Res. 121, 575–583. doi: 10.1161/CIRCRESAHA.117.310624

Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., et al. (2014). CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159, 440–455. doi: 10.1016/j.cell.2014.09.014

Ponjavic, J., Ponting, C. P., and Lunter, G. (2007). Functionality or transcriptional noise? Evidence for selection within long noncoding RNAs. Genome Res. 17, 556–565. doi: 10.1101/gr.636607

Roden, C., Gaillard, J., Kanoria, S., Rennie, W., Barish, S., Cheng, J., et al. (2017). Novel determinants of mammalian primary mRNA processing revealed by systematic evaluation of hairpin-containing transcripts and human genetic variation. Genome Res. 27, 374–384. doi: 10.1101/gr.20890.00.116

Rotllan, N., Price, N., Pati, P., Goedeke, L., and Fernandez-Hernando, C. (2016). microRNAs in lipoprotein metabolism and cardiometabolic disorders. Atherosclerosis 246, 352–360. doi: 10.1016/j.atherosclerosis.2016.01.025

Rouskin, S., Zabrud, M., Washietl, S., Kellis, M., and Weissman, J. S. (2014). Genome-wide probing of RNA structure reveals active unfolding of mRNA structures in vivo. Nature 505, 701–705. doi: 10.1038/nature12894

Siegfried, N. A., Busan, S., Rice, G. M., Nelson, J. A., and Weeks, K. M. (2014). RNA motif discovery by SHAPE and mutational profiling (SHAPE-MaP). Nat. Methods 11, 955–965. doi: 10.1038/nmeth.3029

Simon, M. D., Pinter, S. F., Fang, R., Sarma, K., Rutenberg-Schoenberg, M., Bowman, S. K., et al. (2013). High-resolution Xist binding maps reveal two-step spreading during X-chromosome inactivation. Nature 504, 465–469. doi: 10.1038/nature12719

Snir, M., Christy, T. W., Inoue, K., Nicholson, C. O., Friedersdorf, M., Keene, J. D., et al. (2016). SHAPE reveals transcript-wide interactions, complex structural domains, and protein interactions across the Xist IncRNA in living cells. Proc. Natl. Acad. Sci. U.S.A. 113, 10322–10327. doi: 10.1073/pnas.1600081113

Zampetaki et al.
